valganciclovir + ganciclovir

Valganciclovir + ganciclovir is a combination of two antiviral drugs used primarily for the prevention and treatment of cytomegalovirus (CMV) infections, especially in immunocompromised patients such as those undergoing organ or stem cell transplantation. Valganciclovir is an oral prodrug that is rapidly converted to ganciclovir in the body, providing higher oral bioavailability compared to direct oral administration of ganciclovir. Both drugs act as acyclic guanine nucleoside analogues and inhibit viral DNA synthesis by being phosphorylated within infected cells to their active triphosphate forms, which then competitively inhibit viral DNA polymerase, leading to chain termination and inhibition of viral replication[6][7][8]. This combination may be considered in clinical scenarios where both intravenous (ganciclovir) and oral (valganciclovir) routes are needed or when transitioning between formulations for optimal management of CMV infection[1][3]. The primary indications include prophylaxis and treatment of CMV disease in transplant recipients and other high-risk populations.

Other names

Valganciclovir/Ganciclovir